Role of therapeutic plasma exchange in acute humoral rejection patients undergoing live-related renal transplantation: A single-center experience.
Acute humoral rejection
graft survival
renal transplantation
therapeutic plasma exchange
Journal
Asian journal of transfusion science
ISSN: 0973-6247
Titre abrégé: Asian J Transfus Sci
Pays: India
ID NLM: 101306858
Informations de publication
Date de publication:
Historique:
received:
09
01
2019
accepted:
02
02
2020
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
ppublish
Résumé
Renal transplantation (RT) is the most successful and ideal renal replacement therapy for end-stage renal disease patients. Renal allograft rejection has always been one of the major barriers in successful RT. Our aim was to report the role of therapeutic plasma exchange (TPE) in acute humoral rejection (AHR) patients who underwent live-related RT (LRRT) and their renal allograft outcome at our center. A prospective observational study was conducted from July 1, 2014, to December 31, 2016. Patients with biopsy-proven AHR and treated with TPE along with other lines of treatment after undergoing LRRT were included in the study. ABO-incompatible individuals, pediatric patients, and patients undergoing second transplants were excluded from the study. Clinical history, donor and graft details, management, and patient and graft survival were noted. Of the 1608 patients who underwent LRRT, 49 (37 males, 76%; 12 females, 24%; mean age 39.5 ± 13.3 years) had biopsy-proven AHR (3.04%) and were treated with TPE. A total of 281 TPEs were performed with an average of 5.7 TPE/patient (range 2-12). Of the 49 patients, 38 patients (78%) with favorable response underwent 213 (75.8%) TPEs (average of 5.6 TPE/patient; range: 2-12), whereas 11 patients (22%) with unfavorable response underwent 68 (24.2%) TPEs (average of 6.2 TPE/patient; range: 3-8). Blood urea ( TPE is a safe and effective adjunct therapy for treating AHR patients.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Renal transplantation (RT) is the most successful and ideal renal replacement therapy for end-stage renal disease patients. Renal allograft rejection has always been one of the major barriers in successful RT. Our aim was to report the role of therapeutic plasma exchange (TPE) in acute humoral rejection (AHR) patients who underwent live-related RT (LRRT) and their renal allograft outcome at our center.
MATERIALS AND METHODS
METHODS
A prospective observational study was conducted from July 1, 2014, to December 31, 2016. Patients with biopsy-proven AHR and treated with TPE along with other lines of treatment after undergoing LRRT were included in the study. ABO-incompatible individuals, pediatric patients, and patients undergoing second transplants were excluded from the study. Clinical history, donor and graft details, management, and patient and graft survival were noted.
RESULTS
RESULTS
Of the 1608 patients who underwent LRRT, 49 (37 males, 76%; 12 females, 24%; mean age 39.5 ± 13.3 years) had biopsy-proven AHR (3.04%) and were treated with TPE. A total of 281 TPEs were performed with an average of 5.7 TPE/patient (range 2-12). Of the 49 patients, 38 patients (78%) with favorable response underwent 213 (75.8%) TPEs (average of 5.6 TPE/patient; range: 2-12), whereas 11 patients (22%) with unfavorable response underwent 68 (24.2%) TPEs (average of 6.2 TPE/patient; range: 3-8). Blood urea (
CONCLUSION
CONCLUSIONS
TPE is a safe and effective adjunct therapy for treating AHR patients.
Identifiants
pubmed: 34349459
doi: 10.4103/ajts.AJTS_5_19
pii: AJTS-15-62
pmc: PMC8294439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62-67Informations de copyright
Copyright: © 2021 Asian Journal of Transfusion Science.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Transplant Proc. 2001 Aug;33(5):2770-3
pubmed: 11498154
Transplant Proc. 2014;46(2):474-6
pubmed: 24655992
Ann Lab Med. 2012 Jul;32(4):283-8
pubmed: 22779070
Transplant Proc. 2013 May;45(4):1524-7
pubmed: 23726611
Exp Clin Transplant. 2006 Dec;4(2):506-9
pubmed: 17238848
Nephrourol Mon. 2015 May 23;7(3):e27073
pubmed: 26034746
J Clin Apher. 2003;18(3):103-10
pubmed: 14569599
J Transplant. 2012;2012:193724
pubmed: 22577514
N Engl J Med. 2010 Oct 7;363(15):1451-62
pubmed: 20925547
Immun Ageing. 2019 May 9;16:9
pubmed: 31168309